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Abstract When 22 members of the BrainNet Europe
(BNE) consortium assessed 31 cases with a-synuclein (aS)
immunoreactive (IR) pathology applying the consensus
protocol described by McKeith and colleagues in 2005, the
inter-observer agreement was 80%, being lowest in the
limbic category (73%). When applying the staging protocol
described by Braak and colleagues in 2003, agreement was
only 65%, and in some cases as low as 36%. When mod-
ifications of these strategies, i.e., McKeith’s protocol by
Leverenz and colleagues from 2009, Braak’s staging by
Mu¨ller and colleagues from 2005 were applied then the
agreement increased to 78 and 82%, respectively. In both
of these modifications, a reduced number of anatomical
regions/blocks are assessed and still in a substantial
number of cases, the inter-observer agreement differed
significantly. Over 80% agreement in both typing and
staging of aS pathology could be achieved when applying a
new protocol, jointly designed by the BNE consortium.
The BNE-protocol assessing aS-IR lesions in nine blocks
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offered advantages over the previous modified protocols
because the agreement between the 22 observers was over
80% in most cases. Furthermore, in the BNE-protocol, the
aS pathology is assessed as being present or absent and
thus the quality of staining and the assessment of the
severity of aS-IR pathology do not alter the inter-observer
agreement, contrary to other assessment strategies. To
reach these high agreement rates an entity of amygdala-
predominant category was incorporated. In conclusion,
here we report a protocol for assessing aS pathology that
can achieve a high inter-observer agreement for both the
assignment to brainstem, limbic, neocortical and amyg-
dala-predominant categories of synucleinopathy and the
Braak stages.
Introduction
While evaluating postmortem brains for signs of neuro-
degeneration, the pathologist has to assess numerous
pathologies, both those that one might expect to find based
on the clinical presentation and those that might be found
based on frequent findings of comorbidity. Furthermore,
one must also consider the high rate of unexpected
pathologies that characterise the ageing brain. Operation-
alized criteria have been developed in order to make the
assessment of pathology more reliable and reproducible.
These criteria have, however, rarely been validated even
for some of the pathologies that are both common and carry
a clinical significance [1, 18, 21]. The major prerequisites
for recommendable operationalized criteria are clarity,
reproducibility and validation.
Already in 1984, Kosaka and colleagues [17] made the
first attempt to standardize the assessment of brain pathology
associated with dementia with Lewy bodies (DLB). DLB
cases were divided into brainstem, limbic and neocortical
subtypes. This division formed the basis of the clinical
concept that in Lewy body disorders (LBD) the clinical
manifestation depends on the anatomical distribution of the
pathology [11, 13, 17, 19, 25]. More detailed instructions for
diagnostic procedures when dealing with DLB, including
details for sampling of brain, staining of sections, assessment
and diagnostic rating of lesions were published in 1996 by the
Consortium on DLB International Workshop [19]. These
consensus recommendations were based on work carried out
assessing either hematoxylin–eosin stained sections or
applying ubiquitin immunohistochemistry (IHC).
In 1993, Ueda and colleagues identified a protein they
referred to as the non-Ab component of Alzheimer’s
amyloid, and later in 1997 Polymeropoulos and colleagues
demonstrated that this protein, a-synuclein (aS), was
central to the neurodegenerative process in DLB and
Parkinson’s disease [26, 30]. The era of aS IHC was
subsequently initiated by the report that LBs and LB
associated neurites (LN) were consistently labelled with aS
across this spectrum of disorders [28].
In 2003, Braak and colleagues, following the concept
delineated by Kosaka and colleagues and applying aS IHC,
described a staging hierarchy of LB related pathology [5,
17] (Table 1a). These authors emphasised that aS immu-
noreactive (IR) pathology initially occurs in the dorsal
motor nucleus of vagus and then progresses in an orderly
caudal to rostral direction, ultimately reaching the neo-
cortex. Subsequently in 2005, the DLB consortium revised
their original protocol and recommended aS IHC as the
preferred method of pathological evaluation, added new
brain regions and devised a detailed scoring strategy for the
assessment of the labelled lesions [19, 20] (Table 1c).
Since then, several studies have been published using aS
IHC in combination with the two most commonly used
classification strategies usually referred to as Braak’s
staging and McKeith’s typing of LB disease related
pathology [5, 20]. When assessing a large number of
brains, many of these studies indicate that aS pathology is
not always present as would be predicted according to the
hypothesis of anatomical hierarchy that underpins these
protocols. Thus, some cases remain unclassifiable (17–
51%) if one strictly follows these current assessment rec-
ommendations [13, 18, 22, 23, 31]. Interestingly, in 2008,
Leverenz and colleagues reported that they were able to
increase the number of classifiable cases from 51 to 96%
by modifying the classification strategy originally descri-
bed by McKeith and colleagues (Table 1d) [18, 20]. The
modifications consisted of a reduction in the number of
regions to be examined, more variability in the assessment
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of the severity of LB-related pathology and the addition of
an amygdala-predominant category of synucleinopathy.
Only a few reports have been published assessing the
reproducibility of the recommended staging strategies. The
first report regarding inter-rater agreement showed that
high agreement was reached when six observers rated five
brain regions in 21 cases following a somewhat simplified
version of the original strategy proposed by Braak and
Table 1 Original and modified Braak staging and McKeith typing of Lewy body (LB) related a-synuclein (aS) immunoreactive (IR) pathology
a. Braak staging of LB related pathology from Braak and colleagues from 2003 [5]a
Stage dmV irz LC R SN AC nbM CA2 transent cx (mc) TO cx (mc) Ins cx (hc) GC (hc) T cx (hc) F cx (fc) P cx (fc)
1 1–2 IR
2 1–2 IR 0–2 1–2
3 1–3 IR 1–3 1–2 1–3 1–3 0–2
4 2–3 IR 2–3 2–3 2–3 IR 1–3 1–2 1–2 1–2
5 2–3 IR 2–3 2–3 2–3 IR 2–3 1–3 2 2 1 1 1
6 3 IR 2–3 2–3 3 IR 3 1–3 2–3 2–3 2 2 2 1 1
b. Braak staging of Lewy-body related pathology as applied in Mu¨ller and colleagues from 2005 [21]b
Stage dmV or irz LC R SN CA2 transent cs T cx
1 C?
2 C? C?
3 C? C? C? C?
4 C? C? C? C? C? C?
5 C? C? C? C? C? C? C?
6 C? C? C? C? C? C? C??
c. McKeith typing of LB related pathology from McKeith and colleagues from 2005 [20]c
Type dmV irz LC R SN AC nbM CA2 transent cx (mc) TOcx (mc) Ins cx (hc) GC (hc) T cx (hc) F cx (fc) P cx (fc)
Brainstem 1–3 1–3 1–3 0–2 0–2 0–1 0–1
Limbic 1–3 1–3 1–3 2–3 2–3 1–3 1–3 0–2 0–1
Neocortical 1–3 1–3 1–3 3–4 2–3 2–4 2–4 2–3 1–3 0–2
d. McKeith typing of LB related pathology as modified by Leverenz and colleagues from 2008 [18]d
Type dmV or irze SNe AC GC F cx
Brainstem 1? 1? 0–2 0–1 0
Limbic 1? 1? 2? 1–3 0–1
Neocortical 1? 1? 2? 2? 2?
Amygdala predominant 0–1 0–1 1? 0–1 0
Anatomical regions listed here are those that are recommended to be assessed by Braak and colleagues (Table 1). Abbreviations of anatomical
regions: dmV dorsal motor nucleus of Vagus, irz intermediate reticular zone, LC locus coeruleus, R raphe, SN substantia nigra, AC amygdala,
nbM nucleus basalis of Meynert, CA2 cornu Ammonis of hippocampus region 2, transent cx transentorhinal region, TO cx temporo-occipital
cortex, Ins cx insular cortex, GC gyrus cinguli, T cx temporal cortex, F cx frontal cortex, P cx parietal cortex, fc first order sensory association
areas and premotor areas and/or primary sensory and motor field of neocortex, hc high order sensory association areas and prefrontal areas of the
neocortex, mc mesocortex
a In the original publication, results given in the table as slight (?), moderate (??) and severe (???) aS-IR, corresponding here with 1, 2 and 3,
respectively. Labelling in AC and irz is mentioned in the text as IR noted
b In the publication, presence (C?) or absence of aS-IR is assessed
c The extent of aS-IR pathology: 1 = sparse LBs or neurites, 2 = [1 LB/high power field and sparse neurites, 3 = C4 LBs and scattered
neurites in low power field, 4 = numerous LBs and neurites
d The extent of aS-IR pathology as given above. Note, a case that fulfills criteria for two categories should be assigned to the more neuro-
anatomically rostral category and an amygdala predominant type is added
e Regarding brainstem, limbic and neocortical McKeith type modified by Leverenz and colleagues [13] in medulla (dmV, irz) and SN aS-IR
pathology at the level of 1? noted in either region and in the amygdala predominant aS-IR pathology at the level of 0–1 noted in both regions
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colleagues [5, 21] (Table 1b). Later in 2008, two neuro-
pathologists reached a 58% agreement assessing 89 cases
with LB-related pathology. Each case was represented by 9
brain regions and was classified according to the original
McKeith protocol [18, 20] (Table 1c). The level of agree-
ment between these two assessors increased to 83% when
the proposed modified McKeith typing strategy was
applied [18] (Table 1d).
The objectives of this study were to assess inter-rater
agreement among 22 neuropathologists with two strategies,
the original staging strategy of Braak and colleagues and
the original typing protocol of McKeith and colleagues [5,
20]. The study sought to identify the pitfalls that impact
on the inter-observer agreement to produce a staging
strategy yielding the highest possible agreement in an inter-
laboratory setting combining many participants with
varying experiences of assessing the pathology of DLB.
Furthermore, we evaluated the reproducibility of both the
simplified Braak’s staging previously utilized in the inter-
rater trial by Mu¨ller and colleagues and the recently
launched modification of the McKeith’s typing strategy
proposed by Leverenz and colleagues [18, 21]. Finally, we
applied the new modified protocols designed within
BrainNet Europe (BNE) to assimilate the strength of
Braak’s and McKeith’s strategies with other recent
advances in aS pathology.
Materials and methods
The general working order is summarized in Fig. 1.
Sampling of material
Thirty-one cases were included and the sampling of the
blocks was carried out by one neuropathologist. The
selection of the anatomical regions included in this study
was based on the currently commonly used assessment
strategies, i.e. Braak’s staging and McKeith’s typing of
LB disease related pathology [5, 20]. Furthermore, only
neuroanatomical regions that are known to be easily rec-
ognizable even by an observer lacking substantial training
in neuroanatomy were included [2] (Fig. 2). The cases
included were selected based on that they displayed aS-IR
The participating neuropathologists
Sampling of the material 
Inclusion of cases was based on availability and inclusion of
blocks (Figure 2) was based on the currently applied
staging/typing strategies (5,20)
Material included 31cases with α-synuclein pathology (Table 2)
Production of sections
5 sets of IHC/α-synuclein stained sections
Primary assessment of the five circulating sets
Each participant assessed the sections following the  instructions    
given. Results were sent to the  coordinator.
The reference group
5
2
1
Detailed instructions 
”How to stage α-synuclein immunolabelled
lesions”(Table 1, 3, 4 and Figures 2-4).
Agreement between participating neuropathologists and the reference 
group when assessing α-synuclein immunolabelled lesions when 
following widely accepted published strategies (Table 5, 6)
Staging of selected cases
All α-synuclein stained sections of the 31 cases were
re-assessed jointly under multi-headed microscope and cases
were assigned  a Braak stage and a McKeith type (5,20). 
3
Design of instructions
Detailed instructions in text, Table and Figure format were
designed and an assessment sheet was constructed 
(Tables 1,3,4;  Figures 2-4)
4
Joint assessment
During a consensus meeting held around a multi-headed    
microscope, all 31 cases were examined and discussed.  Pitfalls
were identified and a modified assessment protocol was constructed.
6
Modified assessment protocol
(Figure 5)
Agreement between participating neuropathologists in assessment of 
α-synuclein pathology when following the modified assessment protocol 
illustrated in Figure 5 (Table 8)
The reference group
Re-assessment of data found in the assessment sheets
Following the data found on the assessment sheets  
1) a Braak stage and a McKeith type was given following the
newly designed assessment protocol illustrated in Figure 5.
2) a Braak stage was assigned following the instructions in the
publication of Muller and colleagues from 2005 (Table 1b) (21)
3) a McKeith type was assigned following the instructions in the 
publication of Leverenz and colleagues from 2008 (Table 1d) (18) 
7
The extent of pathology in caudal to rostral direction in cases with  
amygdala-predominant distribution of α-synuclein pathology (Table 7)
Fig. 1 Flowchart
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lesions in various extent. Thus, cases with all stages from
mild to severe involvement with aS-IR lesions were
available for assessment. A total of five sets of 7-lm-thick
sections were produced from 10 brain areas of the 31 cases.
The demographics of the included material are shown in
Table 2.
Immunohistochemistry
Five sets of the ten sampled sections were manually stained
by applying IHC methodology. In brief, after rehydration,
the sections were autoclaved in citrate buffer and pre-
treated with 80% formic acid for 5 min. Subsequently, the
sections were incubated overnight at 4C with a mono-
clonal primary antibody directed against aS (Novocastra/
NCL-ASYN, clone KM51, dilution 1:1,000). The reaction
product was visualized using the Zymed Lab-SA detection
system (Zymed, San Fransisco, CA, USA) with the use of
Biosource Romulin AEC as the chromogen (Biocare
Medical, Walnut Creek, CA, USA).
Reference assessment and construction of assessment
instructions
The members of the reference group (I.A., P.I., H.K., J.I.,
J.B., S.G.) simultaneously assessed all the cases using a
multi-headed microscope (Table 2). The reference group
assigned each case to Braak’s stage and McKeith’s type
according to the original publications from 2003 and 2005
[5, 20]. In addition, the regularity of the caudal to rostral
1. Medulla
2. Pons
1
2
3
3. Midbrain
4
5
8
4. Basal forebrain
5. Striatum
8. Temporal cortex
6
7
7. Cingulate gyrus
6. Hippocampus
9.Frontal cortex 10. Parietal cortex
Fig. 2 Eight of the ten
anatomical regions sampled and
the scanned figures of all
sections with delineation* of
structures to be assessed are
illustrated. 1-medulla with
dorsal motor nucleus of vagus*
and intermediate reticular
zone*; 2-pons with locus
ceruleus* and dorsal raphe
nucleus*; 3-midbrain with
substantia nigra, pars
compacta*; 4-basal forebrain
with amygdaloid nucleus* and
nucleus basalis of Meynert*;
5-striatum with insular cortex*;
6-hippocampus at the level of
lateral geniculate nucleus with
CA2 region* and temporo-
occipital cortex*; 7-gyrus
cinguli grey matter, 8-temporal
cortex, superior and middle*
temporal gyrus, grey matter;
9- frontal cortex, Brodmann
area 9- and 10- parietal cortex,
Brodmann area 39/40
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distribution of pathology was assessed and discrepant cases
were identified as atypical (Table 2). When a prominent
involvement of the amygdala was seen (e.g. amygdaloid
aS pathology present in excess compared to brainstem
involvement), the case was classified as being of amygdala-
predominant type.
Assessment instructions were written by two members
of the reference group (I.A., P.I.). The instructions included
a detailed description of the samples (Fig. 2), photographs
of the pathology to be assessed (Figs. 3, 4), general
instructions regarding assessment (Table 3) and detailed
tabulated guidelines on the staging and typing (Table 1).
Participants were encouraged to read the original publi-
cations.
Inter-observer assessment
Twenty-two participants assessed and staged each case as
instructed. The results were recorded on the assessment
sheets (Table 4) which were collected in the coordinating
Table 2 Demographics of the cases included and the stage of a-synuclein pathology obtained by the reference group following original
instructions
Case Gender Age at
death
Cognitive
impairment
Brain
weight
AD related Braak
stage [7]
a-synuclein immunoreactive pathology
Braak
stage [5]
McKeith
type [20]
Amygdala-
predominant
1 Female 70 1,290 2 1 1
2 Male 75 Yes 1,500 1 2 1
3 Male 57 1,280 0 3 1
4 Male 70 1,535 1 3a 1
5 Male 76 1,680 1 3 1
6 Male 83 1,210 1 3 1
7 Male 62 1,505 0 4 1
8 Female 71 Yes 1,000 2 4 1
9 Female 73 1,440 2 4 1
10 Female 74 1,260 2 4a 1
11 Female 77 1,345 1 4a 1
12 Female 78 1,480 2 4a 1
13 Female 80 1,560 0 4 1
14 Male 78 1,450 1 4 2 Yesb
15 Male 83 Yes 1,395 2 4 2
16 Male 63 1,535 0 5a 2
17 Female 74 Yes 1,255 2 5a 2 Yesb
18 Male 80 1,300 4 5a 2 Yesb
19 Male 76 1,420 1 5 2
20 Male 78 1,600 2 5 2 Yesb
21 Male 68 1,275 0 6 2
22 Female 74 Yes 1,305 6 6 2 Yesb
23 Female 79 Yes 1,090 6 6a 2 Yesb
24 Male 89 1,135 2 6a 2
25 Male 77 1,480 0 6 3
26 Male 67 1,490 2 6 3
27 Male 70 Yes 1,345 1 6 3
28 Male 72 1,460 1 6 3
29 Male 73 1,490 0 6 3
30 Male 74 Yes 1,485 2 6 3
31 Male 83 Yes 1,325 3 6 3
AD Alzheimer’s disease related pathology, i.e. Braak stage of hyperphosphorylated-tau immunoreactive neurofibrillary pathology
a The caudal to rostral progression as given in Table 1a was not regular, i.e. the case is atypical regarding the distribution of pathology
b Amygdala predominant type, i.e. the pathology is most severe in amygdala
640 Acta Neuropathol (2009) 117:635–652
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centre where the data were integrated for analysis. These
assessment sheets included information on whether or not
the participant had identified the target neuroanatomical
regions, whether or not aS pathology was seen, an
assessment of LBs and LNs and the designated stage and
type of each case. In addition, each participant stated
whether the distribution of pathology seemed to progress
as expected (i.e. typical vs. atypical case) and whether
amygdala-predominant synucleinopathy was observed.
Consensus meeting and joint assessment
Following the phase of individual assessment, the group
convened a meeting to jointly assess all IHC labelled
Fig. 3 a-synuclein immunoreactive pathological structures a–d grain like cytoplasmic, b–h intracytoplasmic Lewy body like inclusions, i, j
extracellular Lewy body like inclusions and k–q a-synuclein immunolabelled neurites
Acta Neuropathol (2009) 117:635–652 641
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sections around a multi-headed microscope. The diagnostic
features of each stage were discussed. While assessing the
stained sections under the multi-headed microscope, the
actual observations were compared with the data recorded
in the assessment sheets. Inconsistencies in these obser-
vations were discussed and pitfalls were sought.
Fig. 4 Density of labeling
assessed on a four step scale
from 0 to 3 in dmV dorsal motor
nucleus of vagus; LC locus
ceruleus; SN substantia nigra,
pars compacta; AC amygdala;
Ento entorhinal cortex, cortex
and CA2 region of Ammon’s
horn. Scale 0 represents no
pathological aggregates,
1 some, 2 moderate and
3 numerous pathological
aggregates. The figures illustrate
the progression of the lesions
from mild to severe seen in
9100 (CA2 9200)
magnifications
642 Acta Neuropathol (2009) 117:635–652
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Re-examining the data found in the assessment sheets
Detailed data found in the original assessment sheets were
re-examined and a Braak stage and McKeith type was
assigned following a new modification of original protocols
designed by the members of BNE during the consensus
meeting. In addition, the data in the original assessments
sheets were used to assign a Braak stage as described by
Mu¨ller and colleagues in 2005 (Table 1b) and a McKeith
type as described by Leverenz and colleagues in 2008
Fig. 4 continued
Table 3 Instructions for the assessment of a-synuclein (aS) immunoreactive (IR) Lewy body (LB) related pathology
1. State for each sample (Fig. 2) whether or not (yes/no) the assessable region is included in the section
2. State for each assessable and identified region whether or not (yes/no) aS-IR pathological structures are seen. aS? covers intracytoplasmic
grains, inclusions, extracellular inclusions, aggregates, neurites, threads (Fig. 3)
3. State for the selected regions whether or not (yes/no) aS-IR LB-like lesions are seen. The rounded LB like inclusions may be located in a
neuron or may be extracellular (Fig. 3b–j)
4. State for the selected regions whether or not (yes/no) aS-IR neurites are seen. LB related neurite or neuropil thread is a tiny rounded, fusiform
or strip like IHC/aS? structure in the neuropil (Fig. 3k–q)
5. Assess the density of aS? in each anatomical region. It is recommended but not required to use the magnification 9100 (Fig. 4)
0. no aS-IR in the area of interest
1. sparse/mild aS- IR in x100 magnification only occasional aS-IR structures are seen and in cortex only a few LB-like inclusions are seen in
the whole gyrus
2. moderate aS-IR in x100 magnification scattered aS-IR structures are seen and in cortex patchy/intervening areas lack LB-like inclusions
but neurites might be widespread
3. severe aS-IR in x100 magnification numerous aS-IR structures are seen and in cortex LB-like inclusions are relatively uniformly
distributed with numerous neurites
6. Assign a Braak stage if possible [5]. The progress from stage 1 to stage 6 is not stepwise but instead is continuous, so select a stage that is
most representative
7. Assign a McKeith type if possible [20]. The progress from brainstem predominant to neocortical is not stepwise but instead is continuous
thereby select a stage that is most descriptive
8. In some cases the distribution of the pathology might not be as strict as delineated by Braak and colleagues in 2003 or McKeith and
colleagues from in 2005 [5, 20]. Please indicate as requested in the assessment sheet whether the distribution of the pathology in caudal to
rostral direction is regular i.e. typical, or not i.e. atypical
9. In some cases the distribution of the pathology might not be as strict as delineated by Braak and colleagues in 2003 or McKeith and
colleagues from in 2005 [5, 20]. In some cases an amygdala predominant pattern might be seen i.e. the pathology is most severe in
amygdaloid complex and less pronounced in brainstem areas. State whether the assessed case should be considered as an amygdala
predominant one
Acta Neuropathol (2009) 117:635–652 643
123
Se
ct
io
n 
A
na
to
m
ic
al
 re
gi
on
 
R
eg
io
n 
id
en
tif
ie
d
ye
s/n
o
S-
IR
ye
s/n
o
LB
 li
ke
 
ye
s/n
o
N
eu
rit
es
ye
s/n
o
Ex
te
nt
 o
f 
S-
IR
0,
1,
2,
3
Co
m
m
en
ts
 
N
uc
le
us
 V
ag
us
 
 
 
 
 
 
 
 
 
1.
 m
ed
ul
la
 
In
te
rm
ed
ia
te
 re
tic
ul
ar
 z
on
e 
 
 
lo
cu
s c
er
u
le
us
 
 
 
 
 
 
 
 
 
2.
 p
on
s 
ehpa
R
 
 
3.
 m
id
br
ai
n 
Su
bs
ta
nt
ia
 n
ig
ra
 
 
 
 
 
 
 
eladgy
m
A
 
 
4.
 b
as
al
 fo
re
br
ai
n 
n
u
cl
. B
as
al
is 
of
 M
ey
ne
rt 
 
 
 
 
 
 
5.
 st
ria
tu
m
 
in
su
la
r c
or
te
x 
 
 
 
 
 
 
2
AC
 
 
6.
 h
ip
po
ca
m
pu
s 
te
m
po
ro
-o
cc
ip
ita
l g
yr
us
 
 
 
 
 
 
 
retta
m
yerg
il
ug
nic
s
uryg
.7
retta
m
ye rg
xcla r
o p
meT
.8
retta
m
yerg
xetr
oclat
n
orF
.9
retta
m
yerg
xetr
oclateiraP
.01
*
 A
lw
ay
s 
in
di
ca
te
 w
he
th
er
 o
r 
n
o
t y
o
u
 c
o
u
ld
 id
en
tif
y 
th
e 
re
gi
on
 in
 q
ue
sti
on
  
PL
EA
SE
 H
IG
H
LI
G
H
T 
TH
E 
ST
A
G
E 
(se
e 
In
st
ru
ct
io
ns
) A
ND
 M
AR
K 
W
HE
TH
ER
 T
HE
 C
AS
E 
IS
 
TY
PI
CA
L 
O
R 
A
TY
PI
CA
L 
Br
aa
k 
sta
ge
 (5
): 
 
 
 
 
0 
,  
   
I ,
 
 
 
 
 
II 
,
 
 
 
 
 
III
 
,
 
 
 
 
IV
 , 
   
 V
,  
   
V
I 
M
cK
ei
th
 st
ag
e 
(20
): 
  
 
 
 
Br
ai
ns
te
m
   
   
  L
im
bi
c 
 
 
 
 
 
 
 
 
N
eo
co
rt
ic
al
 
Ca
ud
al
 to
 ro
str
al
 d
ist
rib
ut
io
n 
(5,
20
): 
 ty
pi
ca
l /
 a
ty
pi
ca
l  
   
 
A
m
yg
da
la
 
(A
C)
 pr
ed
om
in
an
t t
yp
e:
  
  
  
ye
s/ 
no
 
T
a
b
le
4
A
ss
es
sm
en
t
sh
ee
t
644 Acta Neuropathol (2009) 117:635–652
123
(Table 1d) [18, 21]. Regarding the assignment of Braak
stage as described by Mu¨ller and colleagues, in the place of
the mesocortical transentorhinal cortex the mesocortical
temporo-occipital cortex was included since this region is
affected to an equivalent extent. The above adjustments did
not require re-assessment of slides as all of the required
data was readily available in the original assessment sheets.
Statistical analysis and photography
The statistical analyses were conducted with SPSS 16 for
Windows. The agreement in the assessments was estimated
applying the nonparametric Wilcoxon rank-sum test. In
addition, the value of absolute agreement (%) was calcu-
lated, that is, the proportion of equal assessments. Digital
images were taken using a Leica DM4000 B microscope
equipped with a Leica DFC 320 digital camera.
Results
The results from the individual assessments (i.e. prior to
the consensus meeting) are summarized in Tables 5 and 6.
All assessors detected aS pathology in all cases and the
agreement of the Braak stage ranged from 32 to 100%
(Table 5) significantly differing in 24 out of 31 cases. All
the assessors were in agreement on the assigned stage in
only 4 out of 31 cases (all cases with Braak stage 6). In 30
out of 31 cases, most of the assessors agreed with the
reference group (except #9). The overall agreement was
65% and agreement was highest in stages 1 (95%) and 6
(79%). In 27% of assessments (24 cases), a lower and in
24% (17 cases) a higher stage was given when compared to
the reference assessment. There was only a 55% agreement
between the assessments when only the twelve cases that
were considered by the reference group as being atypical in
their caudal to rostral distribution of aS pathology or those
assessed to be of the amygdala-predominant type were
included. Agreement increased to 70% only when the 19
cases with a typical distribution of pathology were inclu-
ded. Out of these 19 assessments, 12 differed significantly
(P \ 0.05).
Agreement between assessments of McKeith type
synucleinopathy ranged from 45 to 100% significantly
differing in 11 out of 31 cases (Table 6). All participants
agreed that a case corresponded to the same McKeith type
in only five cases. However, in all cases, the majority of
assessors agreed with the reference group. The overall
agreement was 80%, being highest in brainstem type (86%)
followed by neocortical type (82%). Nine out of 31 cases
(29%) were assigned by some assessors as being of
brainstem, by others they were believed to be limbic and by
yet others as being of neocortical type. There was 73%
agreement between the assessments when the six cases
considered to be of the amygdala-predominant type were
included and the agreement increased from 73 to 83%, if
only the 25 remaining cases were included. Out of these 25
assessments, 8 differed significantly (P \ 0.05).
There was extensive variation in the agreement regard-
ing assessment of typical versus atypical caudal to rostral
propagation. Following the strategy delineated by Braak
and colleagues, most of the individual assessments agreed
with the reference group in six out of the nine atypical
cases (# 11,12,17,18, 23, 24). Overall agreement about
typical versus atypical distribution of pathology exceeded
75% in only 12 out of 31 cases. In only 11 cases did all
assessors agree that the aS pathology displayed a typical
distribution pattern.
According to the reference group, six cases displayed an
amygdala-predominant aS pathology. The majority of the
individual assessments were in agreement in five of these
cases (# 14, 17, 18, 22 and 23). In all six cases, all indi-
vidual assessments noted the substantial aS pathology in
amygdala. In one other case (#20) in contrast to the ref-
erence group, some observers had also observed substantial
pathology in the brainstem (Table 7). In all of the
remaining cases with pathology in the amygdala, the
severity of aS pathology was proportionate to that seen in
the midbrain/brainstem. Nevertheless, 12 of these cases
were considered by some observers to be of the amygdala-
predominant type.
Most of the assessors participated in the consensus
meeting where there was a joint assessment of all cases.
Issues such as whether or not a case fulfilled the staging
requirements (i.e. typical vs. atypical case or whether or
not a case should be labelled as an amygdala-predominant
type) were debated. It became evident that the primary
obstacle was not in microscopic assessment but rather in
the assignment of the Braak stage and the McKeith type
[5, 20]. With respect to the Braak stage, problems were
encountered when all regions were not affected with aS
pathology. The major obstacle in the assignment of
McKeith type was the overlap of aS-IR pathology between
the subtypes. This arose from the lack of clarity in the
difference between brainstem and the limbic categories or
limbic and neocortical categories. After these discussions,
a new modification of the original assessment protocols
referred to as the ‘BNE protocol’ was formulated to
increase the agreement between the assessments (Fig. 5).
The issue of a threshold level of aS pathology was widely
debated, e.g. does a single LN in an anatomical region
indicate that the region is involved and taken into consid-
eration in the modified protocol (Fig. 5). In the newly
designed BNE protocol, 13 anatomical regions repeatedly
identified and found in 9 sampled blocks were included.
Thus, each Braak stage and each McKeith type were
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represented by at least two neuroanatomical regions to
ensure better reproducibility in the assessment results.
Furthermore, the lesions requested to be seen in the region
of interest were defined as being LBs or LNs or both. No
counting of IR lesions was required and only in the case
of the amygdala-predominant category was an arbitrary
assessment of the extent of pathology required (Fig. 5).
Table 8 summarises the assessment results and the rate of
inter-observer agreement while following the BNE protocol
compared to the earlier modifications of the Braak’s staging
and McKeith’s typing of aS pathology [18, 21].
While following the BNE-protocol, the Braak stage
differed in four cases when compared to the original ref-
erence assessment (case 5 Braak stage 3 ? 4; case 9, 12
and 14 Braak stage 4 ? 5/6). The original McKeith type
was altered in 13 cases (cases 5, 7–13 McKeith brain-
stem ? limbic; cases16, 21, 23 and 24 McKeith
limbic ? neocortical). Using the BNE-protocol, the over-
all agreement regarding the Braak stage increased from 65
to 83% and with respect to the McKeith type from 81 to
84%. It is noteworthy that while applying the BNE proto-
cols for Braak staging and McKeith typing, the number of
Table 5 Agreement between the reference group and among 22 assessors in Braak’s staging [5]
Case Reference group Braak stage
Stage given by the 22 participating observers
Absolute agreement in percent Wilcoxon rank-sum test
1 2 3 4 5 6 Single case One stage Overall Single case One stage Overall
1 1 21 1 95 95
2 2 8 14 64 64 * *
3 3 1 7 11 3 50 *
4 3a 5 17 77 63 *
5 3 13 8 1 59 * *
6 3 3 4 14 1 64 *
7 4 8 13 1 59 *
8 4 3 17 2 77 *
9 4 5 8 7 2 32 *
10 4a 8 10 4 45 55 *
11 4a 5 7 10 45 *
12 4a 5 10 6 1 45 * *
13 4 1 19 2 86 65
14 4b 13 4 5 59 *
15 4 10 9 3 45 *
16 5a 3 10 9 45 *
17 5a,b 7 11 4 50 * *
18 5a,b 7 9 6 41 52 * *
19 5 3 12 7 55 *
20 5b 1 15 6 68 *
21 6 1 7 4 10 45 *
22 6b 4 5 13 59 *
23 6a,b 7 15 68 *
24 6a 6 4 12 55 *
25 6 2 3 17 77 79 *
26 6 22 100 *
27 6 22 100
28 6 3 19 86
29 6 3 3 16 73 *
30 6 22 100
31 6 22 100
* P \ 0.05 by means of Wilcoxon rank-sum test are given for a single case, on the level of a Braak stage and overall including all 31 cases
a Atypical distribution
b Amygdala-predominant type as determined by the reference group. Inter-rater agreement given in bold. Absolute agreement and significant
difference
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cases with significantly differing (P \ 0.05) assessments
dropped from 17 to 10 and from 12 to 10 cases,
respectively.
Rather similar agreement was obtained when applying
the strategy proposed by Mu¨ller and colleagues [21],
assessing aS in fewer brain regions. It is noteworthy,
however, that the original assessment results were altered
in as many as 12 cases and some of these alterations were
substantial (case 17 stage 5 ? 3 and case 21 stage 6 ? 3).
The strategy proposed by Leverenz and colleagues [18]
(i.e. assessing fewer brain regions and taking into account
also the amygdala-predominant type) largely followed the
pattern obtained when applying the BNE protocol.
There was one significant difference when comparing
the BNE protocol with the previous modifications of the
widely accepted categorization strategies. If one utilized
the newly designed BNE protocol, then the inter-observer
agreement was 70% or more in most cases (Table 8). The
assessment differed significantly (P \ 0.05) in 14 out of 31
cases when applying the strategy proposed by Leverenz,
when compared with 10 cases when following the protocol
designed by BNE.
Table 6 Agreement among 22 assessors in McKeith’s typing [20]
Case Reference group McKeith type
Type given by the 22 participants
Absolute agreement in percent Wilcoxon-rank-sum test *p \ 0.05
0 Brainstem Limbic Neocortical Single case One type Overall Single case One type Over all
1 Brainstem 22 100
2 Brainstem 22 100
3 Brainstem 21 1 95
4 Brainstem 22 100
5 Brainstem 20 2 91
6 Brainstem 2 20 91
7 Brainstem 19 3 86 85
8 Brainstem 15 7 68 *
9 Brainstem 13 8 1 59 *
10 Brainstem 18 4 82
11 Brainstem 20 2 91
12 Brainstem 15 7 68 *
13 Brainstem 16 6 73 *
14 Limbica 3 16 3 86 *
15 Limbic 3 19 86 81 *
16 Limbic 19 3 86
17 Limbica 4 18 82
18 Limbica 2 18 2 86 73 *
19 Limbic 21 1 95
20 Limbica 1 19 2 86
21 Limbic 7 12 3 55 *
22 Limbica 3 10 9 45 *
23 Limbica 11 11 50 *
24 Limbic 3 14 5 64 *
25 Neocortical 7 15 68 *
26 Neocortical 22 100
27 Neocortical 1 21 95
28 Neocortical 1 8 13 59 82 *
29 Neocortical 4 4 14 64 *
30 Neocortical 22 100
31 Neocortical 2 20 91
* P \ 0.05 by means of Wilcoxon rank-sum test are given for a single case, on the level of a McKeith category and overall including all 31 cases
a Amygdala predominant type as determined by the reference group. Inter-rater agreement given in bold. Absolute agreement and significant
difference
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In the original assessment, six cases (# 11,12,17,18, 23,
24) were considered by most assessors to be atypical with
respect to the caudal to rostral propagation of pathology.
The data recorded in the assessment sheets showed that five
cases (# 4, 17,18, 23, 24) did not fulfil the anatomical
sequence of Braak’s staging in most assessments and these
cases were thus designated as ‘‘staging criteria incom-
pletely fulfilled’’ as recommended by the BNE protocol.
Discussion
Remarkably good agreement, over 80%, was achieved in
this study when 22 observers assessed 31 cases with aS
pathology. It is noteworthy that this high rate of agreement
required modification of both of the widely adopted current
protocols [5, 20].
When designing the tabulated guideline utilized by the
22 observers in this trial, it was clearly noted that the
platform for the assessment of aS pathology is essen-
tially the same when assigning a Braak stage or a
McKeith type [5, 20]. Both strategies are based on the
original work of Kosaka and colleagues [17] and assume
that aS pathology progresses in an orderly caudal to
rostral direction. The main difference between these two
commonly applied protocols is primarily in the selection
of the regions to be assessed. In Braak’s staging, the
outcome is given as a stage of aS pathology and in
McKeith’s typing a more generalized ‘type’ or anatom-
ical category of aS pathology is assigned [5, 20]. The
Table 7 Mean ± standard error (SE) of the semiquantitative assessment of a-synuclein (aS) immunoreactive pathology by 22 observers
Case dmV mean ± SE SN mean ± SE AC mean ± SE GC mean ± SE P cx mean ± SE
14 2.22 ± 0.09 2.17 ± 0.17 3.00 ± 0.13 1.57 ± 0.32 0.39 ± 0.22
17 1.74 ± 0.14 1.74 ± 0.14 3.00 ± 0.20 1.96 ± 0.31 0.13 ± 0.13
18 1.57 ± 0.18 1.83 ± 0.12 2.78 ± 0.11 2.39 ± 0.27 0.26 ± 0.18
20 2.48 ± 0.11 3.17 ± 0.12 3.65 ± 0.12 2.74 ± 0.18 0
22 1.96 ± 0.10 2.35 ± 0.10 3.96 ± 0.43 2.35 ± 0.26 0.13 ± 0.13
23 1.22 ± 0.21 1.30 ± 0.20 4.00 ± 0.00 3.26 ± 0.18 0.65 ± 0.26
T test 0.000 0.000 0.000 0.000
Six cases with amygdala-predominant pathology as assessed by the reference group listed. The extent of pathology in various neuroanatomical
regions differed significantly (T test) when compared with the extent seen in the amygdaloid nucleus
Abbreviations of neuroanatomical regions: dmV dorsal motor nucleus of vagus, SN substantia nigra, AC amygdaloid nucleus, GC gyrus cinguli,
P cx parietal cortex
grey 
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Fig. 5 BrainNet Europe protocol, i.e. assignment of the Braak stage
and McKeith type of a-synuclein (aS) immunoreactive (IR) Lewy
body (LB) disease related pathology as proposed by BrainNet Europe
consortium. dmV Dorsal motor nucleus of vagus, irx intermediate
reticular zone, LC locus coeruleus, R raphe, SN substantia nigra, nbM
nucleus basalis of Meynert, AC amygdala, CA2 cornu Ammonis of
hippocampus, region 2 TOcx temporo-occipital cortex. LN Lewy
neurites. Two to three regions represent each Braak stage. For a Braak
stage only one of the required regions needs to be affected with the
required (LB or LN) aS-IR pathology. Note, if a case does not fulfil
sequentially all Braak stages, it is designated as an IF case, i.e. staging
criteria incompletely fulfilled. For the McKeith brainstem type, one of
the obligatory brainstem regions (medulla, pons, midbrain) has to be
affected with LB and or LN. Only one of the two regions in Limbic or
Neocortical type needs to be affected with the required (LB or LN)
pathology to merit classification to this category. In Amygdala
predominant type, the aS-IR LBs are either noted only in the AC or
they are seen in excess in AC when compared to the brainstem
regions. If occasional aS-IR LNs are seen in AC or in cortical regions
without LBs, the case is assigned as a ‘‘?’’ case, i.e. a Braak stage 3?
or a McKeith brainstem ?, when the case displays LBs and/or LNs up
till midbrain but in addition LNs are seen in neocortical areas
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‘brainstem type’ of the McKeith’s strategy largely cor-
responds to Braak stages 1–3, and the ‘neocortical type’
largely to Braak stages 5 and 6. However, the ‘limbic
type’ of the McKeith strategy can represent Braak stages
3–5, if the assessment instructions are strictly followed
[5, 20].
Table 8 The most frequent Braak stage and McKeith type following original instructions [5, 20], instructions devised by BrainNet Europe
(Fig. 5) and other previously published modifications of original instructions [18, 21]
Case Braak stage McKeith type
Originala
(Table 1a)
Absolute
agreement %
Modified by
BNEb (Fig. 5)
Absolute
agreement %
Simplifiedc by
Mu¨ller et al.
(Table 1b)
Absolute
agreement %
Originald
(Table 1c)
Absolute
agreement %
Modified by
BNEe (Fig. 5)
Absolute
agreement %
Modifiedf by
Leverenz et al.
(Table 1d)
Absolute
agreement %
Stage Single case Stage Single case Stage Single case Stage Single case Stage Single case Stage Single case
1 1 95 1 100 1 100 Brainstem 100 Brainstem 100 Brainstem 100
2 2 64* 2 95 2 95 Brainstem 100 Brainstem 100 Brainstem 100
3 3 50* 3 82 3 64* Brainstem 95 Brainstem 91 Brainstem 91
4 3g 77* 3 86 3 91 Brainstem 100 Brainstem 100 Brainstem 100
5 3 59* 4 64* 3 86 Brainstem 91 Limbic 95 Limbic 68*
6 3 64* 3 55* 3 59* Brainstem 100 Brainstem 100 Brainstem 100
7 4 59* 4 64* 3 82 Brainstem 86 Limbic 73* Limbic 68*
8 4 77* 4 86 3 59* Brainstem 68* Limbic 100 Limbic 100
9 4 36* 5 55* 3 82 Brainstem 59* Limbic 86 Limbic 82
10 4 45* 4 68* 3 68* Brainstem 82 Limbic 82 Limbic 73*
11 4g 45* 4 55* 3 91 Brainstem 91 Limbic 55* Limbic 55*
12 4g 45* 5 41* 3 82 Brainstem 68* Limbic 82 Limbic 95
13 4 86 4 82 3 86 Brainstem 73* Limbic 91 Limbic 95
14 4h 59* 5/6 68* 5/6 55* Limbich 86 Limbic 86 Limbic 73*
15 4 45* 4 64* 4 41* Limbic 86 Limbic 82 Limbic 77*
16 5/6 86 5/6 91 5/6 64* Limbic 86 Neocortical 64* Neocortical 59*
17 5/6g,h 68* 5/6 68* 3 77* Limbich 82 Limbic 95 Limbic 95
18 5/6g,h 68* 5/6 82 4 36* Limbich 86 Limbic 55* Limbic 64*
19 5/6 86 5/6 95 5/6 64* Limbic 95 Limbic 68* Limbic 68*
20 5/6h 95 5/6 91 5/6 68* Limbich 86 Limbic 73* Limbic 73*
21 5/6 64* 5/6 100 3 73* Limbic 55* Neocortical 64* Neocortical 59*
22 5/6h 82 5/6 100 5/6 100 Limbich 45* Limbic 55* Limbic 59*
23 5/6g,h 100 5/6 100 5/6 100 Limbich 50* Neocortical 82 Neocortical 82
24 5/6g 73* 5/6 91 5/6 45* Limbic 64* Neocortical 78* Neocortical 64*
25 5/6 91 5/6 95 5/6 91 Neocortical 68* Neocortical 86 Neocortical 86
26 5/6 100 5/6 100 5/6 100 Neocortical 100 Neocortical 100 Neocortical 100
27 5/6 100 5/6 100 5/6 100 Neocortical 95 Neocortical 100 Neocortical 100
28 5/6 100 5/6 100 5/6 77* Neocortical 59* Neocortical 77* Neocortical 68*
29 5/6 86 5/6 100 5/6 91 Neocortical 64* Neocortical 91 Neocortical 91
30 5/6 100 5/6 100 5/6 100 Neocortical 100 Neocortical 100 Neocortical 100
31 6 100 5/6 100 5/6 95 Neocortical 91 Neocortical 95 Neocortical 95
Absi 74 83 78 81 84 82
Absj 73 83 79 81 86 84
Wk 0.000 0.005 0.001 0.093 0.230 0.002
Wl 0.000 0.000 0.094 0.526 0.000 0.000
Braak stage as given in a Braak et al. 2003 [5], in b Fig. 5 and in c Mu¨ller et al. 2005 [21]. McKeith type as given in d McKeith et al. 2005 [20], in
e Fig. 5 and in f Leverenz et al. 2008 [18]. g IF case = staging criteria incompletely fulfilled, h amygdala-predominant type. The absolute
agreement in percent and significant differences * p\0.05 tested by means of the nonparametric Wilcoxon-rank-sum test are given for a single
case, overall (Absi, Wk) and overall when amygdala predominant cases were excluded (Absj, Wl)
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There is much recent work confirming that the progres-
sion of aS pathology is not as straightforward as originally
presumed and there are several reports which highlight
deviations in the orderly caudal to rostral progression pat-
tern of pathology [11, 12, 16, 18, 22, 23, 29, 31]. One likely
reason why the Braak’s original staging may yield poor
inter-observer agreement is that the staging scheme requires
that each subgroup displays newly affected regions and
worsening impairment of those previously involved [5, 6].
With respects to the McKeith’s typing, lack of clear dif-
ferences between the three categories represents a major
obstacle [20]. Thus, when strictly following the published
instructions, a substantial number of cases remain unclas-
sified, clearly indicating the need for a more universally
applicable paradigm of aS pathology [16, 18, 22, 23, 31].
In this study, applying the original McKeith’s typing
resulted in an overall inter-observer agreement of 81%
which was lowest in the limbic type (73%) [20]. It should
be noted, however, that in 39% of the cases, less than 75%
of the observers agreed on the specific type. Two observers
used the McKeith’s typing to assess 89 cases and achieved
an even lower agreement (58%), and concluded that a
substantial number of their original 208 cases (49%) were
not classifiable [18]. However, they reported that by
reducing the number of regions to be assessed, by adding
an amygdala-predominant entity and by allowing more
variability in the assessment of the severity of LB-related
aS pathology, they were able to categorise 97% of their
cases [18, 20]. They reported 87% agreement between the
two assessors when following their modified criteria. The
existence of the amygdala-predominant category was
already acknowledged by Uchikado and colleagues in 2006
[29]. The 22 observers in the present study reached an 82%
agreement when applying those modified criteria [18], a
performance which was also achieved for the protocol
newly designed by the BNE consortium (84%) during the
joint assessment meeting. Both the modified McKeith’s
typing [18] and the BNE protocol resulted in assignment of
each case to the same category (i.e. brainstem, limbic or
neocortical). The absolute agreement while applying the
Leverenz strategy and the BNE protocol is here probably
primarily due to the selection of material [18]. It should be
noted that these two strategies are not fully comparable. In
all included cases which were of neocortical type, sub-
stantial pathology was seen and thus the Leverenz criteria,
i.e. [1 LB/high power field and sparse neurites were ful-
filled. The BNE-protocol does not require any assessment
of the extent of pathology and thus some cases which are
designated being of neocortical type following BNE-pro-
tocol (aS-IR LBs seen) will fulfill the criteria for limbic
type rather than neocortical while following the strategy
described by Leverenz and colleagues [18]. It is notewor-
thy that the protocol designed by BNE resulted in only six
cases where agreement was below 70% compared to ten
cases following the recently modified McKeith’s strategy
[18]. It is noteworthy that aS pathology in a neuroana-
tomical region not included in the Leverenz modification
but recommended for assessment in the BNE protocol may
alter the result in specific cases [18]. Related issues around
the variability of pathology within individual cases is
therefore an important source of discrepancy, when com-
paring results obtained by different observers who may
have followed different modifications of published
assessment strategies. Furthermore, the clinical and path-
ophysiological significance of aS pathology seen in various
anatomic patterns is still unclear, as was recently stated in a
critical reappraisal of Lewy related pathologies by Jellinger
[14]. Based on the above, a reduction of regions to be
assessed regarding aS pathology is not advisable.
When the results obtained when following the original
instructions published by McKeith and colleagues were
compared to those obtained while following either the
Leverenz modification or the BNE-protocol, it was noted
that 12 cases were allocated to a more ‘rostral’ category (8
cases, brainstem ? limbic; 4 cases, limbic ? neocortical)
[18, 20]. These category shifts might be due to the lack of
detail in the original published criteria. Leverenz and col-
leagues already noted that one of the pitfalls in the original
publication was a lack of stringency, so that they recom-
mended assigning a case that fulfilled criteria for two
categories to the more anatomically rostral category. In
contrast, the BNE-protocol permits cases to be assigned to
only one category to avoid this confusion. The clinical
implications of this shift to a more ‘‘rostral’’ neuropatho-
logical category need to be evaluated as both limbic and
particularly neocortical types are considered to be evidence
of a more severe symptomatology.
When the original Braak protocol was applied, then only
a 65% agreement was reached in the staging of aS pathology
with the agreement being as low as 32% in some cases. Only
in cases in stages 1 or 6 was agreement high. Two issues
influenced this outcome. The variability within each stage
was extensive in those cases where the pathology lay outside
the hypothetical pattern of caudal to rostral progression and
also in cases with amygdala-predominant pathology. Taking
these two issues into account, the agreement increased only
from 65 to 67%. When stages 5 and 6 were combined as in
Table 8, the percentages were still below 80% (74 respective
77). Previously, it was reported that a high agreement could
be reached following a slightly modified Braak protocol
when staging aS pathology in 21 cases by 6 observers [21].
We also applied the strategy described by Mu¨ller and col-
leagues and achieved 78% agreement in the assessments and
the agreement increased to 79% when the six cases of
amygdala-predominant synucleinopathy were excluded.
However, in our study, the results obtained while applying
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the strategy described by Mu¨ller and colleagues differed
significantly from those obtained when applying the original
strategy described by Braak and colleagues and those
obtained when applying the BNE-protocol. In a substantial
number of cases, the Mu¨ller modification resulted in
assignment to a lower stage [5, 21]. This difference is pri-
marily due to the reduced number of neuroanatomical
regions assessed by Mu¨ller and colleagues compared to the
original Braak protocol [5, 21]. Furthermore, on an indi-
vidual case level, the inter-observer agreement differed
significantly in 14 cases when compared to 10 cases when
applying the BNE protocol.
Already in 2006, Uchikado and colleagues [29] noted
while assessing LB pathology in subjects with Alzheimer’s
disease that in some cases an amygdala predominant
distribution of aS pathology was noted. Later, in 2008
Leverenz and colleagues [18] proposed the addition of an
amygdala predominant category to permit a reliable clas-
sification. Here, we also noted that the addition of an
amygdala-predominant category increased the inter-obser-
ver agreement.
Using the nine-block strategy (Fig. 5) proposed by the
BNE protocol, not only is it possible to robustly assign the
aS pathology type, but also a more detailed stage of aS
pathology can be ascribed. Thus, this method is applicable
both to diagnostic and research use. For molecular-biolog-
ical, biochemical or detailed clinico-pathological studies,
we recommend that the aS stages from 0 to 6 and the
assignment to a amygdala-predominant category will be
most appropriate, whereas for routine diagnostic purposes a
more generalized assignment to brainstem, limbic, neocor-
tical or amygdala-predominant categories may be sufficient.
The sampling strategy recommended by BNE and rec-
ommended in the original strategies described by Braak
and colleagues [5] and McKeith [20] and colleagues do not
include the olfactory bulb that has been indicated to be
affected at an early stage in both Alzheimer’s disease [10]
and of PD and DLB [9]. It is, however, relevant to consider
whether this structure, contrary to current general practise
in diagnostic neuropathology, should be routinely sampled
for assessment of neurodegenerative lesions, particularly
when dealing with unimpaired aged subjects. Recently,
the significance of aS pathology in the olfactory bulb in
subjects with DLB was brought forward by Beach and
colleagues [4]. The sensitivity and specificity of aS
pathology in the olfactory bulb for PD and DLB were over
90% and thus the authors concluded that aS pathology
accurately predicted the presence of aS pathology in other
brain regions [4]. They even suggested that olfactory bulb
biopsy should be considered as a diagnostic tool particu-
larly in subjects being assesses for surgical therapy. This
approach was further discussed by others as some negative
biopsy studies regarding aS pathology in the olfactory bulb
have also been reported [15, 24]. Recently, Sengoku and
colleagues [27] assessed 320 consecutive autopsies which
showed aS pathology in 32.9%. However, the olfactory
bulb was involved in only 26.6% further emphasising that
involvement of the olfactory bulb is not seen in all cases
with aS pathology in the central nervous system.
The novel BNE-protocol for designation of both the
stage and the type of aS pathology is based on the assess-
ment of aS-IR in 13 defined neuroanatomical regions in
conjunction with the type of lesions (i.e. LB or LN). This
strategy was devised to avoid one major problem in the
validation of inter-observer methods for evaluating neuro-
degenerative pathology, i.e. the use of numerical counting
of lesions. Previous studies dealing with the assessment of
aS pathology have indicated that it is difficult to achieve
satisfactory agreement on the severity of pathology in even
a core sample of only 2 mm diameter [2]. It was concluded
that since quantitative estimates of aS-IR structures are
unreliable, these should not be included in the assessment
strategy. It is also evident that differing staining methods for
aS pathology yield variable results [2, 3, 8]. Thus, a stan-
dard validated protocol for typing and staging pathology
does require a consistent quality in the stained sections and
an assessment method that delivers reproducible results.
In conclusion, here we report a protocol for assessing aS
pathology, based on a modification of the existing widely
adopted methods that can achieve a high inter-observer
agreement for both the assignment to brainstem, limbic,
neocortical and amygdala-predominant categories of syn-
ucleinopathy and the Braak stages (1–6) when appropriate.
Due to its simplicity, when these BNE-protocols were
applied, it was possible for all cases to be classified, i.e. by
evaluating nine brain regions and only assessing the pres-
ence or absence of aS-IR LBs and LNs.
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